Tag: 3D Signatures

June 22, 2018
May 10, 2018

3D Signatures Strengthens Its Intellectual Property With New Patents Issued for Tests in Alzheimer’s Disease, Hodgkin’s Lymphoma and Multiple Myeloma

3D Signatures Inc. (TSXV:DXD,OTCQB:TDSGF), a personalized medicine company with a proprietary software platform (TeloViewTM) based on the three-dimensional analysis of...
May 4, 2018
April 19, 2018

Genetics Update: Q1 in Review

With Q1 2018 officially in the books, here the Investing News Network takes a look back at what some of...
March 28, 2018

3D Signatures Collaborates with MDxHealth to Evaluate Telo-PC™ Test in Prostate Cancer

3D Signatures Inc. (TSXV:DXD,OTCQB:TDSGF) (the “Company” or "3DS"), a personalized medicine company with a proprietary software platform (TeloViewTM) based on...
March 6, 2018

3D Signatures and l’Institut Universitaire de Cardiologie et de Pneumologie de Québec Announce Collaboration

3D Signatures (TSXV:DXD) a personalized medicine company with a proprietary software platform based on the three-dimensional analysis of chromosomal signatures, is...
March 6, 2018

3D Signatures Inc. and l’Institut Universitaire de Cardiologie et de Pneumologie de Québec (IUCPQ) Announce Collaboration to Combine TeloView™ with Genome Sequence Analysis in Lung Cancer

3D Signatures Inc. (TSX-V:DXD) (OTCQB:TDSGF) (FSE:3D0) (the "Company" or "3DS"), a personalized medicine company with a proprietary software platform based...
March 1, 2018

3D Signatures Reports Quarter Ended December 31, 2017 Financial Results

3D Signatures Inc. (TSXV:DXD) (OTCQB:TDSGF) (FSE:3D0) (the "Company" or "3DS"), a personalized medicine company with a proprietary software platform based...
February 20, 2018

3D Signatures Announces Positive Topline Results of Development Trial Assessing its Telo-HL Test for Hodgkin’s Lymphoma

3D Signa­­­­­­tures (TSXV:DXD) is pleased to announce that a preliminary third-party analysis of the trial data for Telo-HL, 3DS’ test...
February 20, 2018

3D Signatures Inc. Announces Positive Topline Results of Development Trial Assessing its Telo-HL™ Test for Hodgkin’s Lymphoma

3D Signa­­­­­­tures Inc. (TSXV:DXD) (OTCQB:TDSGF) (FSE:3D0) (the "Company" or "3DS") is pleased to announce that a preliminary third-party analysis of...